
News & Media
Follow our news
Learn moreNews

2025-06-13
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy

2025-04-23
PolTREG accelerates the development of next-generation antigen-specific Tregtherapy for Type 1 Diabetes

2025-03-27
PolTREG partners with Noble Capital Markets Inc. to prepare for potential fundraising in the U.S.

2025-03-25
Webinar: PolTREG’s Strategic Collaboration with Antion Biosciences and Growth Prospects for 2025

2025-03-21
PolTREG Forms Strategic Partnership with Antion Biosciences to Develop Next-Generation Allogeneic CAR-Treg Therapies

2025-01-20
PolTREG secures PLN 51.4M grant recommendation from Polish Agency for Enterprise Development for groundbreaking multiple sclerosis therapy

2025-01-09
PolTREG obtains Japanese patent for intrathecal PTG-007 therapy in multiple sclerosis
